CymaBay Therapeutics, Inc. (NASDAQ:CBAY) Q4 2022 Earnings Call Transcript

A team of individuals that have built a team below them to really execute and don’t believe we have any risk as we get to potential top line data in the third quarter as we look to even register seladelpar in €“ on the heels of potential success in the development program as well. So, fundamentally, I’ll tell you, we don’t have any gaps. They don’t see any risk. We’ve just got a tremendous team up and down the organization across functions. Obviously, our goal is to continue to develop the team broadly, including in the CMO function over time, but I think very important for us to now find an individual that complements the team that exists here today. And really can serve us as we think about the next iteration of the company in this transformation potentially from development stage to commercial.

Unidentified Analyst: Excellent. That’s really helpful. Thanks for taking our questions and looking forward to the data in the third quarter.

Sujal Shah: Absolutely. Thank you.

Operator: There are no further questions at this time and I’d like to turn the floor back over to Sujal Shah for any closing comments.

Sujal Shah: Well, thank you all once again for joining us today. As we approach top line data readout and RESPONSE in the third quarter, our activities and presence at medical meetings with healthcare providers, patient advocates, and many others that will play a key role in getting seladelpar to patients, all of these will continue to accelerate. It’s going to be an exciting and busy year ahead and we look forward to sharing updates with you along the way. Thank you.

Operator: This concludes today’s conference. You may disconnect your lines at this time. Thank you for your participation and have a great day.